These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19233604)

  • 1. [Hypertension in obese patients: Pathophysiology and management].
    Girerd X; Hansel B
    Presse Med; 2009 Apr; 38(4):609-13. PubMed ID: 19233604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of arterial hypertension in obese patients.
    Wenzel UO; Benndorf R; Lange S
    Semin Nephrol; 2013 Jan; 33(1):66-74. PubMed ID: 23374895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary hypertension: obesity and the metabolic syndrome.
    Singer GM; Setaro JF
    J Clin Hypertens (Greenwich); 2008 Jul; 10(7):567-74. PubMed ID: 18607142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating essential hypertension. The first choice is usually a thiazide diuretic.
    Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and insulin disorders.
    Imazu M
    Curr Hypertens Rep; 2002 Dec; 4(6):477-82. PubMed ID: 12419178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of obesity-induced hypertension.
    Kotsis V; Stabouli S; Papakatsika S; Rizos Z; Parati G
    Hypertens Res; 2010 May; 33(5):386-93. PubMed ID: 20442753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients.
    Seravalle G; Colombo M; Perego P; Giardini V; Volpe M; Dell'Oro R; Mancia G; Grassi G
    Hypertension; 2014 Aug; 64(2):431-7. PubMed ID: 24866140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sympathetic nervous system and insulin resistance: from obesity to diabetes.
    Esler M; Rumantir M; Wiesner G; Kaye D; Hastings J; Lambert G
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):304S-309S. PubMed ID: 11721888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.
    Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME
    Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and treatment of the obesity-related arterial hypertension.
    Kolanowski J
    Acta Clin Belg Suppl; 1992; 14():18-25. PubMed ID: 1604957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.
    Kalil GZ; Haynes WG
    Hypertens Res; 2012 Jan; 35(1):4-16. PubMed ID: 22048570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment.
    Richards RJ; Thakur V; Reisin E
    J Hum Hypertens; 1996 Sep; 10 Suppl 3():S59-64. PubMed ID: 8872829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hypertension in the patients with obesity].
    Hano T; Nishio I
    Nihon Rinsho; 2001 May; 59(5):973-7. PubMed ID: 11392001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipokines: novel players in resistant hypertension.
    de Faria AP; Modolo R; Fontana V; Moreno H
    J Clin Hypertens (Greenwich); 2014 Oct; 16(10):754-9. PubMed ID: 25186286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension.
    Engeli S; Sharma AM
    Curr Opin Cardiol; 2002 Jul; 17(4):355-9. PubMed ID: 12151869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a rationale for angiotensin blockade in the management of obesity hypertension?
    Sharma AM
    Hypertension; 2004 Jul; 44(1):12-9. PubMed ID: 15173127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin resistance and arterial hypertension].
    Weidmann P; Müller-Wieland D; de Courten M; Krone W
    Herz; 1995 Feb; 20(1):16-32. PubMed ID: 7713473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors that influence the risk of hypertension in obese individuals.
    Coatmellec-Taglioni G; Ribière C
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):305-8. PubMed ID: 12698070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.